Bradley Jeffrey D, Perez Carlos A, Dehdashti Farrokh, Siegel Barry A
Department of Radiation Oncology, Mallinckrodt Institute of Radiology, St. Louis, Missouri, USA.
J Nucl Med. 2004 Jan;45 Suppl 1:96S-101S.
18F-FDG PET offers the radiation oncology community the ability to incorporate biologic information into radiation therapy targets. To date, most of the work in this arena has involved patients with non-small cell lung cancer (NSCLC). The literature suggests that biologic targeting with PET alters the radiation treatment volume significantly in 30%-60% of NSCLC patients for whom definitive therapy is planned. This is mostly the result of the incorporation of regional nodes with 18F-FDG avidity that were previously judged to be uninvolved by CT criteria. The development of the integrated PET/CT scanner is a valuable tool that improves diagnostic accuracy for staging this disease and will increase the accessibility of PET for radiation treatment planning. Its implementation into radiation treatment planning requires strong collaboration between radiation oncologists and nuclear physicians. In this report, we will review the literature on PET-based radiation treatment planning, its potential benefits, and future challenges.
18F-FDG PET为放射肿瘤学界提供了将生物学信息纳入放射治疗靶区的能力。迄今为止，该领域的大部分工作都涉及非小细胞肺癌（NSCLC）患者。文献表明，对于计划进行根治性治疗的NSCLC患者，30%-60%的患者采用PET进行生物学靶向会显著改变放射治疗体积。这主要是因为纳入了先前根据CT标准判断为未受累但具有18F-FDG摄取的区域淋巴结。一体化PET/CT扫描仪的开发是一种有价值的工具，可提高该疾病分期的诊断准确性，并将增加PET在放射治疗计划中的可及性。将其应用于放射治疗计划需要放射肿瘤学家和核医学医师之间的密切合作。在本报告中，我们将回顾基于PET的放射治疗计划的文献、其潜在益处和未来挑战。
